News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioIndustry Association's UK CEO and Investor Forum Will Showcase Recent Deals and Fund Raisings


5/31/2013 10:46:18 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

31 May 2013 -- The BioIndustry Association’s (BIA) UK CEO and Investor Forum, the UK’s leading event for bioscience executives, will be held on 10-11 July 2013. The focus of the agenda will be on the key issue for the UK bioscience sector – financing.

With its mixture of analysis and insight into the sector's key issues, the UK CEO and Investor Forum is an excellent way to gain insight into how to add value to your company. Regardless of what's going on elsewhere, the sector has much to celebrate, from the successful Biomedical Catalyst scheme and news on exits, to significant fundraising and even signs of life in the IPO market. Add in a large medicinal dose of networking with the who’s who of the sector and a central location and this is the go-to event for the senior team.

The forum will provide attendees the opportunity to learn from and meet investors and leaders from across the sector ranging from experienced chief executives and board members to the CEO of the UK’s newest biotech company – Oliver Hardick, of OneStart competition winners Puridify Ltd, who received complementary BIA membership as part of their prize. Steve Bates, BIA Chief Executive Officer, said:

“The UK CEO and Investor Forum will give bioscience leaders the opportunity to hear from our excellent line-up of speakers on the key issues to help them drive their businesses forward in the current economic environment, meet key investors such as Rockspring Ventures, Arthurian Life Sciences, Apposite Capital and Syncona Partners and feed back into the BIA’s policy agenda.”

Oliver Hardick, CEO of Puridify Ltd, said:

“I am looking forward to attending the BIA’s UK CEO and Investor Forum to meet and learn from other executives in the sector. The kind advice that we have received to date has allowed us to gain recognition and I hope forum will provide an opportunity to make new connections to aid the success of Puridify.”

Ed Hodgkin, a Partner at Syncona Partners, said:

“Syncona Partners will be attending the UK CEO and Investor Forum to build essential connections, identify new investment opportunities and network with the newest UK bioscience companies.”

For further information, please contact Robert Winder, Head of Communications, rwinder@bioindustry.org, 020 7630 2191; mobile 07825 942 934.

UK CEO and Investor Forum

The UK CEO and Investor Forum will take place at Down Hall, Hatfield Heath, Hertfordshire, on Wednesday 10 and Thursday 11 July. On Wednesday 10 July the BIA will host a networking drinks reception, three-course evening dinner and a fireside chat with Patrick Verheyen, Head, Johnson & Johnson Innovation Centre in London. The second day will include a plethora of presentations and panel discussions on issues that are essential for success in these challenging times. Attendees at the 2013 UK CEO and Investor Forum will have the chance to learn from success, meet key investors and provide the tools needed to build a valuable bioscience company. For more information visit http://bit.ly/BIACEO2013 The confirmed agenda includes sessions on the future for R&D and the sector over the next decade, “If I’d known then what I know now...” the beauty of CEO hindsight discussed and debated, accessing finance and profitable partnerships including case studies of recent fundraisings and deals, New funds and new money, non debt financing, what you need to know about the new NHS – and how recent changes have made it easier to run clinical trials in the UK and the value and opportunities of social media for bioscience companies

Confirmed speakers include:

• Dr Mark Carnegie-Brown, Chief Executive Officer, Glide Pharma

• Sinclair Dunlop, Managing Partner, Rockspring Ventures

• Matthew Durdy, Chief Finance Officer, Cell Therapy Catapult

• Dr Daniel Elger, Chief Financial Officer, e-therapeutics

• Professor Sir Chris Evans OBE, Chairman, Arthurian Life Sciences

• Sam Fazelli, Director of European Research. Senior Analyst, Healthcare, Bloomberg

• David Hipkiss, Chief Executive Officer, Prosonix

• Dr Ed Hodgkin, Partner, Syncona Partners and BIA Board

• Dr Chris Hollowood, Partner, Syncona Partners

• Allan Marchington, Partner, Apposite Capital and BIA Board

• Charles Mayo, Head of Life Sciences, Simmons & Simmons

• Simon Quayle, Director, Digital Communications, GlaxoSmithKline

• Dr Oliver Rausch, Programme Director, Translational Research Partnerships, NIHR

• Dr Christian Rohlff, Chief Executive Officer, Oxford BioTherapeutics

• Mark Russon, Business Development Manager, UK Primary Markets, London Stock Exchange

• Dr Andrew Slade, Managing Director, Menirini Biotech

• Patrick Verheyen, Head, Johnson & Johnson Innovation Centre, London

Puridify Ltd

Puridify is a UCL spinout commercialising purification solutions for biotherapeutic manufacture. The patented technology behind the spinout was developed by Puridify CEO Oliver Hardick during his Engineering Doctorate at UCL in collaboration with the Science & Technology Facilities Council. The technology, FibroSelect - a novel chromatography reagent, aims to reduce downstream processing costs by 90% thereby overcoming current limitations with downstream processing operations which typically account for over 50% of the processing costs. www.puridify.com

BioIndustry Association

Founded over 20 years ago at the infancy of biotechnology, the BioIndustry Association (BIA) is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector. The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives. For further information, please go to www.bioindustry.org



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES